Determination of Optimal Fermentation, Processing and In Vitro Conditions in a Cell-Free Protein Production System

无细胞蛋白质生产提供了很有前途的新途径，然而，今天的生产任何种类的定制 重组蛋白可能需要数周时间。一种经济可行的无细胞蛋白表达方法的研制 平台可以对加快生物分子研究产生重大影响。此外，它还可以使 新疗法的发现、生产和交付，包括重组蛋白，它代表着一种 相当大的机会。 Liberum Biotech(Liberum)是一家蛋白质制造服务提供商，旨在使获得 合成生物学的成果。Liberum是安大略省多伦多的一家初创公司，其服务使用专有技术 分子和硬件技术，以加快酶、治疗药物和实验室试剂的生产。 具体地说，他们的技术自动化了蛋白质的表达和纯化，以减少时间和成本 制造基于蛋白质的疗法所必需的。尽管Liberum技术很强大，但进一步的增强 并进行优化。与兰伯顿学院的合作项目将专注于扩大规模 用于大规模生产无细胞蛋白质生产系统的发酵和下游工艺。 为此，将采用试验性方法来优化Liberum的流程，以支持大规模 制作。 开发一种改进的无细胞生产工艺将使Liberum能够显著降低 它的产品，提高利润率，并为下一年吸引240万美元的种子资金。该项目还将 允许在接下来的几个月里在Liberum设立两个新的就业职位。自.以来 许多合成生物学和无细胞蛋白质生产公司已经在美国成立。 在各国，该项目的成功将支持这一新兴颠覆性部门的创新和增长， 推动加拿大在下一代蛋白质生产方面取得进展。

Cell-free protein production offers promising new avenues, however, today's production of any sort of custom recombinant protein can take weeks. The development of an economically feasible cell-free protein expression platform can have a significant impact on speeding up biomolecular research. As well, it can enable the discovery, production, and delivery of new therapeutics including recombinant proteins, which represents a sizeable opportunity. Liberum Biotech (Liberum) is a provider of protein manufacturing services intended to democratize access to the fruits of synthetic biology. A start-up company in Toronto, Ontario, Liberum's services use proprietary molecular and hardware technology to speed up the production of enzymes, therapeutics, and lab reagents. Specifically, their technology automates protein expression and purification to reduce the time and cost required for making protein-based therapeutics. Although Liberum technology is robust, further enhancements and optimization are needed. The collaborative project with Lambton College will focus on the scale-up fermentation and downstream processes for large-scale manufacturing of cell-free protein production systems. To do this, an experimental approach will be adopted to optimize Liberum's processes in support of large-scale production. Developing an improved cell-free production process would allow Liberum to significantly reduce the cost of its product, increase its margin, and attract $2.4 million in seed funding for the next year. The project will also allow for the creation of two new employment positions in Liberum over the following months. Since numerous synthetic biology and cell-free protein production companies have been established in the United States, the success of this project will support innovation and growth of this emerging disruptive sector and move Canada forward in next-generation protein production.